Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Promega Luciferase is Smaller, Brighter, and More Versatile

Published: Friday, June 01, 2012
Last Updated: Friday, June 01, 2012
Bookmark and Share
NanoLuc™ technology enables better reporter applications and more.

Promega Corporation has announced the launch of a novel luciferase that is smaller, brighter, and more versatile than any current bioluminescent enzyme.

These attributes of the NanoLuc™ Luciferase provide new capabilities in reporter assays with potential in biologically complex applications that require greater sensitivity.

NanoLuc technology includes a novel substrate, furimazine, developed by Promega organic chemists and a unique enzyme developed by Promega research scientists using directed evolution techniques.

It has unparalleled small size allowing for enhanced viral delivery and protein fusion applications, and it is easily secreted from cells.

The enzyme is two orders of magnitude brighter than either firefly (Photinus pyralis) or Renilla reniformis luciferases resulting in better performance in hard to transfect cells.

Also, NanoLuc performs in more physiologically relevant models including complex biological samples.

With add and measure simplicity and a stable signal, NanoLuc Luciferase can be scaled from bench-top to high-throughput screening applications with no modifications.

To meet the many application needs in a ‘next-gen’ genetic reporter, 12 plasmid versions of NanoLuc Luciferase are available.

The offerings include NanoLuc-PEST (NlucP), which closely couples protein expression to changes in transcriptional activity and increased signal-to-background ratios.

For a secreted reporter, a NanoLuc Luciferase construct has been prepared by fusion to an N-terminal secretion signal (secNluc).

Using the Nano-Glo™ Luciferase Assay Reagent, luminescence is linear over a 1,000,000-fold concentration range with a signal half-life =2 hours.

NanoLuc Luciferase possesses a host of physical properties that make it an excellent reporter protein. See www.promega.com/nanoluc for more information.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Promega to Break Ground for New Processing and Manufacturing Facility
Facility will allow for efficiency improvements for processing, packaging, staging and shipping products.
Monday, July 07, 2014
Promega and MyBio Sign Exclusive Distribution Agreement
New partnership gives researchers and scientists in the University, Government and Commercial Laboratory Sector improved access to Promega’s world class product range.
Wednesday, June 12, 2013
Promega Corporation Building New Facility to Support Regulated Product Manufacturing
cGMP facility to accommodate business growth and customers who need FDA-regulated molecular biology products.
Tuesday, September 06, 2011
Promega Expansion into Brazil Brings New Convenience and Support for Scientists
Now scientists in life science research, drug discovery and clinical diagnostics have direct access to technical service, fast delivery and the ability to request a quote online in Brazil.
Thursday, April 07, 2011
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!